Tacrolimus trough level at discharge predicts acute rejection in moderately sensitized renal transplant recipients

Transplantation

Volumn 97, Issue 10, 2014, Pages 986-991

  Richards, Katelyn R ^a   Hager, David ^a   Muth, Brenda ^a   Astor, Brad C ^b   Kaufman, Dixon ^a   Djamali, Arjang ^a  

^a University of Wisconsin Health   (United States)

^b UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

Calcineurin; Immunosuppression; Rejection; Sensitized

Indexed keywords

TACROLIMUS;

ACUTE GRAFT REJECTION; ADULT; ANTIBODY SPECIFICITY; ARTICLE; BK VIRUS INFECTION; CLINICAL EVALUATION; CYTOMEGALOVIRUS INFECTION; DISEASE ASSOCIATION; DRUG EFFECT; FEMALE; FOLLOW UP; GRAFT RECIPIENT; GRAFT SURVIVAL; HOSPITAL DISCHARGE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY GRAFT; KIDNEY GRAFT REJECTION; MAJOR CLINICAL STUDY; MALE; POSTOPERATIVE PERIOD; PREDICTION; PRIORITY JOURNAL; SENSITIZATION; SURVIVAL RATE; SURVIVAL TIME; VIREMIA;

BIOPSY; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOLLOW-UP STUDIES; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INCIDENCE; KIDNEY FAILURE, CHRONIC; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; SURVIVAL RATE; TACROLIMUS; TREATMENT OUTCOME;

EID: 84901268183     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0000000000000149     Document Type: Article

References (20)

1. Organ Procurement and Transplantation Network (OPTN) and ScientificRegistry of Transplant Recipients (SRTR).OPTN/SRTR 2010Annual Data Report. Rockville, MD: Department of Health and Human Services, Health Resources and Services Administration, Healthcare Systems Bureau, Division of Transplantation; 2011.
2. Webster AC, Woodroofe RC, Taylor RS, et al. Tacrolimus versus cyclosporin as primary immunosuppression for kidney transplant recipients: meta-analysis and meta-regression of randomized trial data. BMJ 2005; 331: 810.
3. Kramer BK, Montagnino G, Del Castillo D, et al. Efficacy and safety of tacrolimus compared with cyclosporine A microemulsion in renal transplantation: 2 year follow up results. Nephrol Dial Transplant 2005; 20: 968.
4. Rowshani AT, Scholten EM, Bernelman F, et al. No difference in degree of interstitial Sirius redYstained area in serial biopsies from area under concentration-over-time curves-guided cyclosporine versus tacrolimustreated renal transplant recipients at one year. J Am Soc Nephrol 2006; 17: 305.
5. Meier-Kriesche HU, Kaplan B. Cyclosporine microemulsion and tacrolimus are associated with decreased chronic allograft failure and improved long-term graft survival as compared to Sandimmune. Am J Transplant 2002; 2: 100.
6. Ihara H, Shinkuma D, Ichikawa Y, et al. Intra- and interindividual variations in the pharmacokinetics of tacrolimus (FK506) in kidney transplant recipientsVimportance of trough levels as a practical indicator. Int J Urol 1995; 2: 151.
7. Jusko WJ. Analysis of tacrolimus (FK506) in relation to therapeutic drug monitoring. Ther Drug Monit 1995; 17: 596.
8. Wong KM, Shek CC, Chau KF, et al. Abbreviated tacrolimus areaunder- the-curve monitoring for renal transplant recipients. Am J Kidney Dis 2000; 35: 660.
9. Scholten EM, Cremers SC, Schoemaker RC, et al. AUC-guided dosing of tacrolimus prevents progressive systemic overexposure in renal transplant recipients. Kidney Int 2005; 67: 2440.
10. Allow RA, Isaacs R, Lake K, et al. Report of the American Society of Transplantation Conference on immunosuppressive drugs and the use of generic immunosuppression. Am J Transplant 2003; 3: 1211.
11. van Gelder T, ESOT Advisory Committee on Generic Immunosuppression. European Society for Organ Transplantation Advisory Committee recommendations on generic substitution of immunosuppressive drugs. Transpl Int 2011; 24: 1135.
12. Alloway RR, Sadaka B, Trofe-Clark J, et al. A randomized pharmacokinetic study of generic tacrolimus versus reference tacrolimus in kidney transplant recipients. Am J Transplant 2012; 12: 2825.
13. Ensor CR, Trofe-Clark J, Gabardi S, et al. Generic maintenance immunosuppression in solid organ transplant recipients. Pharmacotherapy 2011; 31: 1111.
14. Singh N, Djamali A, Lorentzen D, et al. Pretransplant donor-specific antibodies detected by single-antigen bead flow cytometry are associated with inferior kidney transplant outcomes. Transplantation 2010; 90: 1079.
15. Niederhaus SV, Muth B, Lorentzen DF, et al. Luminex-based desensitization protocols: the University of Wisconsin initial experience. Transplantation 2011; 92: 12.
16. Kidney Disease: Improving Global Outcomes (KDIGO) Transplant Work Group. KDIGO clinical practice guidelines for the care of kidney transplant recipients. Am J Transplant 2009; 9(suppl 3): S1.
17. Staatz C, Taylor P, Tett S. Low tacrolimus concentrations and increased risk of early acute rejection in adult renal transplantation. Nephrol Dial Transplant 2001; 16: 1905.
18. Borobia AM, Romero I, Jimenez C, et al. Trough tacrolimus concentrations in the first week after kidney transplantation are related to acute rejection. Ther Drug Monit 2009; 31: 436.
19. O'Seaghdha CM, McQuillan R, Moran AM, et al. Higher tacrolimus trough levels on days 2Y5 post-renal transplant are associated with reduced rates of acute rejection. Clin Transplant 2009; 23: 462.
20. Bouamar R, Shuker N, Hesselink DA, et al. Tacrolimus predose concentrations do not predict the risk of acute rejection after renal transplantation: a pooled analysis from three randomized-controlled clinical trials. Am J Transplant 2013; 13: 1253.